Investigational new toxicology for drugs to treat alzheimer's disease and other aging related diseases
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN260200400010C
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,481,940
Award facts
- Opportunity
-
- 2600405 Solicitation number
- Contract value 130% obligated
- $4,228,000.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$793,949 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,332,238 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,292,488 | |
| Other Administrative Action | $0 | |
| Modification | $0 | |
| Funding Only Action | $1,253,940 | |
| Original award | $2,397,223 |
About this award
Sri International, a nonprofit research and development organization headquartered in Menlo Park, California, was awarded a definitive cost-plus-fixed-fee contract by the National Institute on Drug Abuse (NIDA) on September 30, 2004, with an ultimate completion date of June 30, 2010. The contract, valued at approximately $4.2 million, supports investigational new drug toxicology research for therapeutic candidates targeting Alzheimer's disease and other age-related conditions. The work will be performed at Sri International's Menlo Park facility, and no small business set-aside was used for this procurement.
This contract represents NIDA's investment in preclinical toxicology evaluation services necessary to advance drug development programs within the National Institutes of Health portfolio. Sri International's multidisciplinary research capabilities and established experience conducting safety and toxicology studies for federal agencies positioned the organization to deliver the specialized scientific services required for evaluating the safety profiles of investigational compounds. The cost-plus-fixed-fee structure reflects the nature of research services where costs cannot be fully predetermined, allowing flexibility to accommodate the variable requirements typical of drug toxicology assessment work.
Quick answers
Who was awarded contract HHSN260200400010C?
HHSN260200400010C was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2004.
How much is contract HHSN260200400010C worth?
The government has obligated $5,481,940 on HHSN260200400010C. Its current value, with exercised options, is $4,228,000.
Was contract HHSN260200400010C competed?
The extent of competition for HHSN260200400010C was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award